Hematopoiesis News Volume 12.16 | May 4 2021

    By
    Justin.choi
    -
    0
    60






    HN 12.16 | May 4 2021


    Hematopoiesis News by STEMCELL Technologies
    Vol. 12.16 – 4 May, 2021
    TOP STORY

    Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia

    Recipients of less-intensive therapies were older, had more comorbidities, more adverse cytogenetics, and worse Karnofsky performance status.
    [Blood]

    Abstract

    Explore scientific events this May with the Science Events Calendar.
    PUBLICATIONSRanked by the impact factor of the journal

    MAEA Is an E3 Ubiquitin Ligase Promoting Autophagy and Maintenance of Hematopoietic Stem Cells

    Researchers report that Macrophage-Erythroblast Attacher (MAEA), a receptor thus far only identified in erythroblastic island, was a membrane-associated E3 ubiquitin ligase subunit essential for HSC maintenance and lymphoid potential.
    [Nature Communications]

    Full Article

    Identification of Therapeutic Targets of the Hijacked Super-Enhancer Complex in EVI1-Rearranged Leukemia

    The authors unraveled key components of G2DHE-bound transcription factors involved in the deregulation of EVI1.
    [Leukemia]

    Full Article

    Cancer-Associated POT1 Mutations Lead to Telomere Elongation without Induction of a DNA Damage Response

    The authors tested the effects of CAS9‐engineered caPOT1 mutations in human embryonic and hematopoietic stem cells.
    [EMBO Journal]

    Full ArticleGraphical Abstract

    LAMP-5 Is an Essential Inflammatory-Signaling Regulator and Novel Immunotherapy Target for Mixed Lineage Leukemia-Rearranged Acute Leukemia

    Scientists found that LAMP5 was a direct target of the oncogenic MLL-fusion protein. LAMP5 depletion significantly inhibited leukemia cell growth in vitro and in vivo.
    [Haematologica]

    Abstract

    3D Bioprinting Allows the Establishment of Long-Term 3D Culture Model for Chronic Lymphocytic Leukemia Cells

    The authors exploited for the first time 3D bioprinting to advance in vitro models for chronic lymphocytic leukemia (CLL). They monitored over time CLL cells viability, phenotype and gene expression, thus establishing a reproducible long-term 3D culture model for leukemia.
    [Frontiers in Immunology]

    Full Article

    3’UTR-Truncated HMGA2 Overexpression Induces Non-Malignant In Vivo Expansion of Hematopoietic Stem Cells in Non-human Primates

    Researchers showed for the first time in vivo multilineage and multiclonal expansion of non-human primate HSCs expressing a 3’UTR truncated version of HMGA2 without evidence of any hematologic malignancy more than seven years post-transplantation.
    [Molecular Therapy-Methods & Clinical Development]

    AbstractFull Article

    Prognostic Factors in Salvage Transplantation for Graft Failure following Allogeneic Hematopoietic Stem Cell Transplantation

    Scientists developed a comprehensive prognostic scoring system consisting of patient and comorbidity factors with 470 patients as a training cohort out of 940; these patients underwent salvage stem cell transplantation for graft failure.
    [Bone Marrow Transplantation]

    Abstract

    Comparing Outcomes of a Second Allogeneic Hematopoietic Cell Transplant Using HLA-Matched Unrelated versus T-cell Replete Haploidentical Donors in Relapsed Acute Lymphoblastic Leukemia: A Study of the Acute Leukemia Working Party of EBMT

    Investigators compared outcomes using HLA-matched unrelated donors versus haploidentical donors in a relapsed acute lymphoblastic leukemia population.
    [Bone Marrow Transplantation]

    Abstract

    Hematologic Malignancies with Unfavorable Gene Mutations Benefit from Donor Lymphocyte Infusion with/without Decitabine for Prophylaxis of Relapse after Allogeneic HSCT: A Pilot Study

    To evaluate the tolerance and efficacy of prophylactic donor lymphocyte infusion in patients with unfavourable gene mutations such as FLT3‐ITD, TP53, ASXL1, DNMT3A or TET2, scientists performed a prospective, single‐arm study.
    [Cancer Medicine]

    Full Article

    Be sure the cells you’re gene editing are still HSPCs with StemSpan™ SFEM II culture medium.
    REVIEWS

    CAR T-Cell Therapy in Multiple Myeloma: More Room for Improvement

    The authors provide a comprehensive analysis on the current manufacturing technologies, and deliberate on the future of CAR T-cell domain in multiple myeloma.
    [Blood Cancer Journal]

    Full Article

    INDUSTRY AND POLICY NEWS

    CARISMA Therapeutics Establishes Collaboration with Leading Cell Therapy Expert to Explore and Develop Allogeneic CAR-Macrophages

    CARISMA Therapeutics Inc. announced it has established a multi-year scientific collaboration with Bruce Blazar, MD, Regents Professor of Pediatrics, Division of Blood and Marrow Transplantation and Cellular Therapy at the University of Minnesota to investigate and develop allogeneic macrophage therapies.
    [CARISMA Therapeutics (PR Newswire LLC.)]

    Press Release

    Tessa Therapeutics Announces Enrollment of 12 Patient Pilot Cohort in its Relapsed or Refractory Hodgkin Lymphoma Phase II Study

    Tessa Therapeutics Ltd. announced enrollment of 12 patient Pilot cohort of its Phase II trial in relapsed/refractory Classical Hodgkin Lymphoma (R/R cHL). The next step in the two-part study is enrollment of the 82 patient Pivotal cohort to assess the safety and antitumor efficacy of Tessa’s autologous CD30 CAR-T in R/R cHL.
    [Tessa Therapeutics Ltd.]

    Press Release

    FEATURED EVENT

    Congress of the European Hematology Association

    June 9 – 17, 2021
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Senior Scientist – Hematopoiesis and Blood Diseases

    St. Jude Children’s Research Hospital – Memphis, Tennessee, United States

    Research Associate / Postdoc – Histone Methyltransferases in Hematopoiesis

    Technische Universität Dresden – Dresden, Germany

    Postdoctoral Researcher Fellowships – Center for Stem Cell and Regenerative Medicine

    Zhejiang University – Zhejiang, China

    Senior Postdoctoral Scientist – AML and Related Cancers

    Cyprus Cancer Research Institute – Cyprus Republic

    Research Scientist – Cancer Flow Cytometry

    Memorial Sloan Kettering Cancer Center – New York, New York, United States/p>

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Hematopoiesis News Twitter

    Brought to you by